Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer

查看全文 作　　者：Dong [1]Wang;Ruikai [1]Du;Suling [2,3]Liu

机构地区：[1]The CAS Key Laboratory of Innate Immunity and Chronic Disease,Hefei National Laboratory for Physical Sciences at the Microscale,School of Life Science and Medical Center,University of Science &Technology of China;[2]Key Laboratory of Breast Cancer in Shanghai,Cancer Institute,Department of Breast Surgery,Fudan University Shanghai Cancer Center;[3]Institutes of Biomedical Sciences,Fudan University

出　　处：《Chinese Journal of Cancer》索引2017年第36卷第6期,共2页

基　　金：supported by National Natural Science Foundation of China grants(Nos.81530075 and 81472741);the National Key Research and Development Program of China(Stem Cell and Translational Research 2016YFA0101202);the Ministry of Science and Technology(MOST) grant (No.2015CB553800) 摘　　要：Breast cancer susceptibility gene 1(BRCA1)is a tumor suppressor gene,and its protein BRCA1 plays a role in DNA repair[1].BRCA1 is generally expressed in the cells of mammary glands and other tissues,helping to repair damaged DNA or disrupting cells when DNA cannot be repaired.When BRCA1 is mutated and cannot function and therefore the damaged DNA cannot be repaired 关键词：PARP抑制剂乳腺癌干细胞蛋白 DNA修复 BRCA1 阴性抑癌基因

相关文献

参考文献（10）
引证文献（1）
耦合文献（18）

参考文献(10)

引证文献(1)

耦合文献(18)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer

参考文献(10)

引证文献(1)

耦合文献(18)

用户提示